1Q-25 Quarterly Results Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of the Company's business plan and strategies. These stat ...

Core Insights - Teladoc Health reported a consolidated revenue of $629.4 million for Q1 2025, a decrease of 3% compared to $646.1 million in Q1 2024 [5][6] - The company experienced a net loss of $93.0 million, or $0.53 per share, which is an increase in loss compared to $81.9 million, or $0.49 per share, in the previous year [7][26] - Adjusted EBITDA for Q1 2025 was $58.1 million, down 8% from $63.1 million in Q1 2024 [11][47] Financial Performance - Revenue breakdown: Access fees revenue decreased by 6% to $525.7 million, while other revenue grew by 16% to $103.6 million [6][28] - U.S. revenue decreased by 4% to $525.0 million, while international revenue increased by 6% to $104.4 million [6][28] - Integrated Care segment revenue increased by 3% to $389.5 million, while BetterHelp segment revenue decreased by 11% to $239.9 million [6][32] Loss and Expenses - The net loss included a non-cash goodwill impairment charge of $59.1 million, which contributed significantly to the overall loss [7][9] - Total costs and expenses for Q1 2025 were $749.98 million, compared to $733.25 million in Q1 2024 [26] - Stock-based compensation expense decreased to $25.2 million from $42.3 million in the previous year [27] Cash Flow and Capital Expenditures - Cash flow from operations was $15.9 million, an increase from $8.9 million in Q1 2024 [12] - Capital expenditures were $31.6 million, down from $35.5 million in the previous year [12] Strategic Developments - Teladoc announced the acquisition of UpLift Health Technologies for $30 million, aimed at enhancing its BetterHelp segment [13] - The acquisition is expected to expand access to virtual mental health services for consumers [13] Future Outlook - For the full year 2025, the company expects revenue between $2.468 billion and $2.576 billion, with adjusted EBITDA projected between $263 million and $304 million [16] - The second quarter 2025 outlook includes expected revenue of $614 million to $633 million and adjusted EBITDA of $56 million to $70 million [18]

Core Insights - Solid Biosciences Inc. is participating in The Citizens Life Sciences Conference on May 7, 2025, with CEO Bo Cumbo leading a fireside chat [1][2] Company Overview - Solid Biosciences is focused on developing precision genetic medicines targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, and catecholaminergic polymorphic ventricular tachycardia [3] - The company is advancing a diverse pipeline of gene therapy candidates and innovative technologies aimed at improving gene therapy delivery across the industry [3] - Solid Biosciences was founded by individuals directly impacted by Duchenne, emphasizing its mission to enhance the daily lives of patients with rare diseases [3]

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform. LifeMD’s weight management program is one of the fastest-growing cash-pay offerings in the countr ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEM ...

Acquisition Establishes Clinical and Operational Foundation for LifeMD's Comprehensive Women's Health Offering, Launching Summer 2025 LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc ...

Core Viewpoint - The European Commission has granted marketing authorization for VYJUVEK, a gene therapy for treating dystrophic epidermolysis bullosa (DEB) from birth, marking a significant milestone for Krystal Biotech and patients in need of this therapy [2][4][5]. Group 1: Product Approval and Features - VYJUVEK (beremagene geperpavec-svdt) is approved for patients with DEB who have mutations in the COL7A1 gene, aiming to provide wound healing through the delivery of functional copies of the gene [2][6]. - The therapy can be administered at home or in healthcare settings, with the option for patient or caregiver administration if deemed appropriate by healthcare professionals [2][3]. - This approval allows for the marketing of VYJUVEK across all EU member states, as well as Iceland, Norway, and Liechtenstein, with the first launch planned in Germany by mid-2025 [3][4]. Group 2: Clinical Evidence and Development - The approval was based on positive recommendations from the European Medicines Agency and comprehensive clinical data from Phase 1/2 GEM-1 and Phase 3 GEM-3 studies, demonstrating successful gene delivery and durable wound closure [4][5]. - VYJUVEK is the first corrective medicine approved in Europe for DEB, highlighting its significance in addressing a high unmet medical need [2][5][7]. Group 3: Company Overview and Future Plans - Krystal Biotech is a global biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs, with VYJUVEK being its first commercial product [7][8]. - The company is also pursuing approval for VYJUVEK in Japan, with a decision expected in the second half of 2025 [5].

Core Points - The Centers for Medicare & Medicaid Services (CMS) has revised the effective date of the Medicare Local Coverage Determination (LCD) for skin substitute products to January 1, 2026, which is used to treat diabetic foot ulcers and venous leg ulcers [1][3] - This action follows a January 2025 executive order by President Trump that froze all regulatory guidance not yet in effect, leading to a previous delay of the LCD's effective date by sixty days [3] - Celularity Inc. expressed support for CMS's decision, highlighting the importance of access to skin substitute products for Medicare patients to avoid serious health complications [4] Company Overview - Celularity Inc. is a regenerative and cellular medicine company focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies [5] - The company aims to leverage the unique biology of the placenta to create effective, accessible, and affordable therapeutic solutions for significant unmet global health needs [5]

Core Viewpoint - Organogenesis supports the U.S. Centers for Medicare & Medicaid Services' (CMS) decision to delay local coverage determinations (LCDs) for skin substitute grafts and cellular and tissue-based products to review coverage policies, emphasizing the importance of high-quality evidence of effectiveness for patient access [1][2] Group 1: Company Position and Recommendations - The company advocates for an integrated coverage and payment policy to address rising Medicare costs while ensuring patient access to effective products [2] - Organogenesis has been a leader in regenerative medicine for four decades, innovating in advanced wound care therapies and bioengineered living cell products [2] - The company emphasizes the role of real-world evidence in demonstrating product safety, efficacy, and clinical outcomes [2] Group 2: Company Overview - Organogenesis Holdings Inc. focuses on the development, manufacture, and commercialization of solutions for advanced wound care and surgical and sports medicine markets [3] - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3]

Core Viewpoint - Organogenesis Holdings Inc. will report its first quarter financial results for fiscal year 2025 on May 8, 2025, after market close [1] Group 1: Financial Reporting - The financial results will be discussed in a conference call scheduled for 5:00 p.m. Eastern Time on the same day [2] - Participants can access the live webcast through the company's website, and the webcast will be archived for approximately one year [2] Group 2: Company Overview - Organogenesis Holdings Inc. is a leading company in regenerative medicine, focusing on advanced wound care and surgical and sports medicine markets [3] - The company offers a comprehensive portfolio of innovative regenerative products to meet patient needs across the continuum of care [3]